On Friday December 12, researchers revealed the most advanced test that can foresee a normal woman’s chances of developing breast cancer. This new test is more efficient than the other strategies that doctors have depended on in the past.
This new test is the first and foremost to blend multitudes of genes and unique characteristics such as age and childbearing to measure the probability of getting breast cancer in women without a pronounced family history of this dreadful disease. Three-fourth of all cases are women who have no family history of breast cancer.
While testing its legitimacy, a California study precisely categorized 50 percent more women with breast cancer as high risk than the existing system did and correctly tallied others lower. The reveal was announced at a cancer convention in Texas
Even though this test, as well as others, affirming to foresee risks are available, specialists suggest that more research is needed to substantiate their merit.
An uncomplicated test has been desired by both doctors and women for years that could disclose the threat of breast cancer apart from the two BRCA genes. These genes are prone to cause cancer at earlier stages of life, but they are a factor in a scarce percentage of all cases. There are four companies that have begun to sell more expansive multi-gene tests, but their validity is broadly contested.
Recurring mammograms or MRI scans are recommended for women who are considered to be at high risk. Some women may even contemplate taking hormone-blocking drugs such as tamoxifen.
The new Onco Vue test is made by a the Oklahoma City-based InterGenetics Inc. company. To avoid disapproval, it is providing the test through doctors only, instead of directly to consumers and proving reliability by using population studies such as the one revealed on Friday.
The test, which costs $397, searches for 22 modifications in 19 genes that have been traced to breast cancer. Around the country, 33 sites provide the test. First women complete a medical form and then gargle with a mouthwash that unleashes cheek cells that are put into a test tube to be evaluated. These factors are measured by a computer model that rates the cancer risk.
This test includes elements of the risk assessment tool that scientists and doctors use currently-the Gail model, which is named after Dr. Mitchell Gail, the National Cancer Institute biostatistician who created it two decades ago. Some of the elements of the test are age, how many family members have had breast cancer and when a woman first had children or had their first period.
Even though the model is pretty rough and has several restrictions, doctors greatly depend on it. The Internet site for it is sought after about 25,000 times a month.
0 Responses to “New test improves prediction of breast cancer”